Figure 1

Enhanced responsiveness of Df1/+ mice to MK801 is reversed by GABA_A α2/α3 receptor agonist, SL651498. (a–c) Enhanced response of male Df1/+ mice to MK801 (a, c). Bretazenil attenuated enhanced locomotion of Df1/+ mice by MK801 (b, c). MK801 (0.32 mg kg⁻¹) was intraperitoneally injected (b) with or (a) without bretazenil (10 mg kg⁻¹). Ambulatory distance is shown in 5 min bins for 60 min after drug administration (a, b) and quantification of ambulatory distance for 60 min is shown in (c). Values are the mean±s.e.m. for 6–16 male mice. ^*P=00071; NS, not significant. (d–g) SL651498 (e), but neither zolpidem (d) nor L655708 (f), attenuated enhanced locomotion of Df1/+ mice by MK801. MK801 (0.32 mg kg⁻¹) was intraperitoneally injected to male Df1/+ and control mice with Zolpidem (0.62 or 3.1 mg kg⁻¹) (d, g), SL651498 (1 or 3 mg kg⁻¹) (e, g) and L655708 (5 or 15 mg kg⁻¹) (f, g). Ambulatory distance is shown in 5 min bins for 60 min after drug administration (e–g) and quantification of ambulatory distance for 60 min is shown in (g). Values are the mean±s.e.m. for 6–16 male mice. ^*P=0.0043.